Respiratory Infections Clinical Trial
Official title:
A Clinical Trial of Nebulized Surfactant for the Treatment of Moderate to Severe COVID-19
Lung surfactant is present in the lungs. It covers the alveolar surface where it reduces the work of breathing and prevents the lungs from collapsing. In some respiratory diseases and in patients that require ventilation this substance does not function normally. This study will introduce surfactant to the patients lungs via the COVSurf Drug Delivery System
The hypothesis behind the proposed trial of surfactant therapy for COVID-19 infected patients requiring ventilator support is that endogenous surfactant is dysfunctional. This could be due to decreased concentration of surfactant phospholipid and protein, altered surfactant phospholipid composition, surfactant protein proteolysis and/or oedema protein inhibition of surfactant surface tension function and/or oxidative inactivation of surfactant proteins. Variations of these dysfunctional mechanisms have been reported in a range of lung diseases, including cystic fibrosis and severe asthma, and in child and adult patients with ARDS. Our studies of surfactant metabolism in adult ARDS patients showed altered percentage composition of surfactant PC, with decreased DPPC and increased surface tension-inactive unsaturated species, and decreased concentrations of both total PC and phosphatidylglycerol (PG) The SARS-CoV-2 virus binds to the angiotensin converting enzyme-2 (ACE2) receptor, which is preferentially expressed in the peripheral lung ATII cells. Consequent viral infection of ATII cells could reduce cell number and impair the capacity of the lungs to synthesise and secrete surfactant. This, however, has not yet been demonstrated empirically in COVID-19 patients. If this is the case, then exogenous surfactant administration to the lungs is potential one treatment option to mitigate disease severity in these patients. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT00369759 -
An Epidemiological Study to Evaluate the RSV-Associated Lower Respiratory Track in Infections in Infants
|
N/A | |
| Completed |
NCT01907659 -
Viral Testing and Biomarkers to Reduce Antibiotic Use for Respiratory Infections
|
N/A | |
| Completed |
NCT00388921 -
High/Low Dose Vit A in Diarrhea/ALRI in Severe PEM
|
N/A | |
| Completed |
NCT02211729 -
A Trial of Seasonal Malaria Chemoprevention Plus Azithromycin in African Children
|
Phase 3 | |
| Recruiting |
NCT03093220 -
Molecular Typing of Community-acquired Pneumonia Based on Multiple-omic Data Analysis
|
N/A | |
| Recruiting |
NCT01167686 -
Effects of Gardemont S.A Food Supplement on Upper Respiratory Illness
|
Phase 2 | |
| Completed |
NCT00514670 -
A Randomized Controlled Trial of a School Disinfection and Hand Hygiene Program
|
N/A | |
| Completed |
NCT02927743 -
Effect of Evidence-based Reminders on Use of Antibiotics
|
N/A | |
| Completed |
NCT02438293 -
'The Impact of Rhinovirus Infections in Paediatric Cardiac Surgery'
|
||
| Completed |
NCT00533182 -
Influenza in People With Normal and Weakened Immune Systems
|
||
| Completed |
NCT01909128 -
Fermented Milk and Fermented Rice on the Appearance of Respiratory and Gastrointestinal Symptoms
|
Phase 3 | |
| Completed |
NCT00144040 -
Improving Antibiotic Use in Acute Care Treatment
|
N/A | |
| Recruiting |
NCT05474430 -
Estimating Risk of Respiratory Infections Attributable to CFTR Heterozygosity
|
||
| Completed |
NCT01443728 -
Vitamin D for Sickle-cell Respiratory Complications
|
Phase 2 | |
| Completed |
NCT02491164 -
Exploratory Study of Intrapulmonary Microdosing of Gram-negative Optical Imaging Detection Probe
|
Early Phase 1 | |
| Completed |
NCT01390753 -
Role of Human Milk Bank in the Protection of Severe Respiratory Disease in Very Low Birth Weight Premature Infants
|
N/A |